We are thrilled to announce that a major milestone was reached this month with 2000 patients enrolled on the SPECTA platform. This success was only made possible thanks to the active network of investigators. We thank them and all patients for their tremendous contribution to clinical cancer research.
SPECTA offers facilitated access to cancer patients’ samples and clinical data to answer translational research questions on cancer and provides solid evidence in guiding targeted future clinical cancer research to treat patients effectively.
The platform started recruitment in 2019 with the AYA, Arcagen, and IMMUcan projects and continues to develop with Bioradon and soon the MRD (Minimal Residual Disease) project.